Govern R&D decisions
with evidence
Intangia transforms fragmented biomedical evidence into decision-ready governance for capital allocation, leveraging burst detection with control axis scoring, translational pathway analysis, and theme/combination intelligence.
Govern R&D decisions
with evidence
Intangia transforms fragmented biomedical evidence into decision-ready governance for capital allocation, leveraging burst detection with control axis scoring, translational pathway analysis, and theme/combination intelligence.
Govern R&D decisions
with evidence
Intangia transforms fragmented biomedical evidence into decision-ready governance for capital allocation, leveraging burst detection with control axis scoring, translational pathway analysis, and theme/combination intelligence.
Overview
Overview
Overview
Fragmented evidence in
structured actions out
Fragmented evidence in
structured actions out
Fragmented evidence in
structured actions out
Evidence stream
Continuously ingests literature, patents, trials, market signals, and optional internal data to capture the full scientific and competitive landscape.
Translation engine
Analyzes how evidence evolves over time to detect emerging momentum, translational pathways, and novel combinations before consensus forms.
Decision artifacts
Produces Momentum Intelligence, prioritization matrices, and FTO outputs designed for portfolio reviews and governance workflows.
Capital actions
Supports go/kill/resize decisions, platform vs. asset allocation, BD screening, and ongoing portfolio rebalancing
The engine
The reasoning layer
that turns signals into actions
Early signal detection
Identifies non-obvious surges in evidence around mechanisms and pathways, validated against matched controls to separate real signal from noise.
Pathway translation
Emerging themes
Explainable rationale
The engine
The reasoning layer
that turns signals into actions
Early signal detection
Identifies non-obvious surges in evidence around mechanisms and pathways, validated against matched controls to separate real signal from noise.
Pathway translation
Emerging themes
Explainable rationale
The engine
The reasoning layer
that turns signals into actions
Early signal detection
Identifies non-obvious surges in evidence around mechanisms and pathways, validated against matched controls to separate real signal from noise.
Pathway translation
Emerging themes
Explainable rationale
Benefits
R&D capital allocation
without guesswork.
Make better R&D and partnering decisions by integrating translational, competitive, and IP evidence all in one place.
Faster Decisions
Move from signal to conviction without fragmented analysis or manual stitching.
Lower Strategic Risk
Reduce exposure to narrative-driven bets with evidence-linked decision trails.
Early Momentum Insight
See emerging targets, mechanisms and indications before they become consensus.
Governance-Ready Output
Produce traceable decision artifacts that investment committees and leadership can stand behind.
Benefits
R&D capital allocation
without guesswork.
Make better R&D and partnering decisions by integrating translational, competitive, and IP evidence all in one place.
Faster Decisions
Move from signal to conviction without fragmented analysis or manual stitching.
Lower Strategic Risk
Reduce exposure to narrative-driven bets with evidence-linked decision trails.
Early Momentum Insight
See emerging targets, mechanisms and indications before they become consensus.
Governance-Ready Output
Produce traceable decision artifacts that investment committees and leadership can stand behind.
Benefits
R&D capital allocation
without guesswork.
Make better R&D and partnering decisions by integrating translational, competitive, and IP evidence all in one place.
Faster Decisions
Move from signal to conviction without fragmented analysis or manual stitching.
Lower Strategic Risk
Reduce exposure to narrative-driven bets with evidence-linked decision trails.
Early Momentum Insight
See emerging targets, mechanisms and indications before they become consensus.
Governance-Ready Output
Produce traceable decision artifacts that investment committees and leadership can stand behind.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Use Cases
Where evidence turns
into defensible decisions
Drug hunting
Prioritising early targets based on translational momentum.
Comparing mechanisms before committing platform resources.
Asset repurposing
Identifying indications where an existing asset shows emerging traction.
Building evidence to support internal repurposing decisions.
Indication expansion
Identify adjacent indications where translational momentum is emerging ahead of consensus.
Support expansion decisions with evidence-linked rationale for internal and board review.
Portfolio prioritisation
Compare programs using a consistent, auditable evidence framework.
Allocate capital toward durable momentum rather than narrative-driven bets.
Built for
Built for
Built for
Supporting those who decide
where R&D capital goes.
Supporting those who decide
where R&D capital goes.
Supporting those who decide
where R&D capital goes.
Biotech Companies
For ambitious biotechs expanding scientific and clinical scope. Capital is available; the constraint is deciding which expansion bets merit backing.
Biopharma & Pharma
For larger organisations allocating capital across many competing portfolios, disease areas, and platforms. Governance requires repeatable, auditable decision processes.
Business Development Teams
For teams licensing, partnering, or positioning assets in crowded and competitive landscapes. The challenge is separating durable momentum from transient hype.
Life Sciences Investors
For venture, growth, crossover, and public market investors seeking an edge ahead of pricing and consensus.
Built to scale
Your custom data.
Your edge. Your magic.
Private Data Integration
Seamlessly bridge your internal research via Snowflake, Databricks, or AWS.
Proprietary Alpha
Overlay your private data onto our evidence layer to unlock custom indicators.
Enterprise-level Security
Every strategic expansion is backed by full auditability and enterprise security and access control.
Built to scale
Your custom data.
Your edge. Your magic.
Private Data Integration
Seamlessly bridge your internal research via Snowflake, Databricks, or AWS.
Proprietary Alpha
Overlay your private data onto our evidence layer to unlock custom indicators.
Enterprise-level Security
Every strategic expansion is backed by full auditability and enterprise security and access control.
Built to scale
Your custom data.
Your edge. Your magic.
Private Data Integration
Seamlessly bridge your internal research via Snowflake, Databricks, or AWS.
Proprietary Alpha
Overlay your private data onto our evidence layer to unlock custom indicators.
Enterprise-level Security
Every strategic expansion is backed by full auditability and enterprise security and access control.
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
”Intangia serves as our decision support layer for R&D and portfolio strategy. It helps us prioritise indications with scientific rationale rather than guesswork”
VP Strategy
Mid-Cap Biotech
“We identified 5 potential partners in weeks instead of the 5-6 months it would normally take. Intangia surfaces companies by mechanism of action, not just therapeutic area.”
CEO
Olgram Therapeutics
“The investor exposure pages saved us hours analysing which funds are active in gene therapy. We immediately see who's deploying capital and where.”
Corporate Development
Sarepta Therapeutics
FAQ
FAQ
FAQ
Got questions?
Start here.
WHAT CAN INTANGIA DETECT?
Intangia detects emerging scientific trends before they become visible to competitors. We identify which biological targets, mechanisms, modalities, and therapeutic combinations are gaining momentum in research, before they hit mainstream attention. This includes patterns across papers, patents, and clinical trials that signal genuine innovation waves rather than noise.
Who is it for?
Intangia is built for pharmaceutical decision makers who need predictive foresight, not reactive search: R&D Strategy Leaders identifying next generation targets and mechanisms BD Teams prioritising partnership opportunities with systematic screening Investment Teams sourcing early stage deals and validating thesis timing IP Strategy Leaders finding white space areas for defensive positioning Corporate Strategy Teams allocating capital to high momentum areas If your job involves answering "what should I be looking at?" rather than "what do I already know about?", Intangia is for you.
How does it work?
Intangia processes millions of papers, patents, and clinical trials to extract meaningful scientific entities: targets, mechanisms, diseases, modalities. We then apply proprietary burst detection algorithms with multi-algorithm consensus and statistical validation to identify when specific concepts suddenly accelerate together. This creates innovation waves. Clusters of related concepts showing coordinated momentum. We track how these waves translate from research into patents and clinical trials, giving you validated predictions about what's emerging. You get momentum scores, translation probabilities, and company level intelligence. Not search results.
Is my data private?
Yes. Intangia processes public scientific data (papers, patents, clinical trials), but your usage, queries, searches, and strategic focus areas remain completely private. We don't share customer activity with anyone. Your competitive intelligence stays yours. If you connect internal data sources (optional), those remain siloed within your organisation's instance.
How do I get started?
We typically begin with a focused pilot on a specific therapeutic area or target class relevant to your pipeline. This lets you validate Intangia's predictive accuracy against known outcomes and recent developments in your field. From there, we expand coverage based on your strategic priorities. Get in touch or book a demo.
WHAT CAN INTANGIA DETECT?
Intangia detects emerging scientific trends before they become visible to competitors. We identify which biological targets, mechanisms, modalities, and therapeutic combinations are gaining momentum in research, before they hit mainstream attention. This includes patterns across papers, patents, and clinical trials that signal genuine innovation waves rather than noise.
Who is it for?
Intangia is built for pharmaceutical decision makers who need predictive foresight, not reactive search: R&D Strategy Leaders identifying next generation targets and mechanisms BD Teams prioritising partnership opportunities with systematic screening Investment Teams sourcing early stage deals and validating thesis timing IP Strategy Leaders finding white space areas for defensive positioning Corporate Strategy Teams allocating capital to high momentum areas If your job involves answering "what should I be looking at?" rather than "what do I already know about?", Intangia is for you.
How does it work?
Intangia processes millions of papers, patents, and clinical trials to extract meaningful scientific entities: targets, mechanisms, diseases, modalities. We then apply proprietary burst detection algorithms with multi-algorithm consensus and statistical validation to identify when specific concepts suddenly accelerate together. This creates innovation waves. Clusters of related concepts showing coordinated momentum. We track how these waves translate from research into patents and clinical trials, giving you validated predictions about what's emerging. You get momentum scores, translation probabilities, and company level intelligence. Not search results.
Is my data private?
Yes. Intangia processes public scientific data (papers, patents, clinical trials), but your usage, queries, searches, and strategic focus areas remain completely private. We don't share customer activity with anyone. Your competitive intelligence stays yours. If you connect internal data sources (optional), those remain siloed within your organisation's instance.
How do I get started?
We typically begin with a focused pilot on a specific therapeutic area or target class relevant to your pipeline. This lets you validate Intangia's predictive accuracy against known outcomes and recent developments in your field. From there, we expand coverage based on your strategic priorities. Get in touch or book a demo.
WHAT CAN INTANGIA DETECT?
Intangia detects emerging scientific trends before they become visible to competitors. We identify which biological targets, mechanisms, modalities, and therapeutic combinations are gaining momentum in research, before they hit mainstream attention. This includes patterns across papers, patents, and clinical trials that signal genuine innovation waves rather than noise.
Who is it for?
Intangia is built for pharmaceutical decision makers who need predictive foresight, not reactive search: R&D Strategy Leaders identifying next generation targets and mechanisms BD Teams prioritising partnership opportunities with systematic screening Investment Teams sourcing early stage deals and validating thesis timing IP Strategy Leaders finding white space areas for defensive positioning Corporate Strategy Teams allocating capital to high momentum areas If your job involves answering "what should I be looking at?" rather than "what do I already know about?", Intangia is for you.
How does it work?
Intangia processes millions of papers, patents, and clinical trials to extract meaningful scientific entities: targets, mechanisms, diseases, modalities. We then apply proprietary burst detection algorithms with multi-algorithm consensus and statistical validation to identify when specific concepts suddenly accelerate together. This creates innovation waves. Clusters of related concepts showing coordinated momentum. We track how these waves translate from research into patents and clinical trials, giving you validated predictions about what's emerging. You get momentum scores, translation probabilities, and company level intelligence. Not search results.
Is my data private?
Yes. Intangia processes public scientific data (papers, patents, clinical trials), but your usage, queries, searches, and strategic focus areas remain completely private. We don't share customer activity with anyone. Your competitive intelligence stays yours. If you connect internal data sources (optional), those remain siloed within your organisation's instance.
How do I get started?
We typically begin with a focused pilot on a specific therapeutic area or target class relevant to your pipeline. This lets you validate Intangia's predictive accuracy against known outcomes and recent developments in your field. From there, we expand coverage based on your strategic priorities. Get in touch or book a demo.
